Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Rhode

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Clinical Immunology (Orlando, Fla.)|June 30, 2006
Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion proteinHeather J Belmont, Shari Price-Schiavi, Bai Liu, et al.
Thrombosis and Haemostasis|January 12, 2010
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding siteJin-an Jiao, Andrew B Kelly, Ulla M Marzec, et al.
Frontiers in Immunology|February 10, 2023
A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in miceXiaoyun Zhu, Qiongzhen Li, Varghese George, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 20, 2022
Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cellsPallavi Chaturvedi, Varghese George, Niraj Shrestha, et al.
Cancer Immunology Research|October 30, 2015
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsPeter R Rhode, Jack O Egan, Wenxin Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsKim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2021
Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8<sup>+</sup> T cell immunity against solid tumorsBai Liu, Xiaoyun Zhu, Lin Kong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2015
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell LymphomasMaximillian Rosario, Bai Liu, Lin Kong, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2024
A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapyNiraj Shrestha, Michael J Dee, Pallavi Chaturvedi, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Clinical Immunology (Orlando, Fla.)|June 30, 2006
Potent antitumor activity of a tumor-specific soluble TCR/IL-2 fusion proteinHeather J Belmont, Shari Price-Schiavi, Bai Liu, et al.
Thrombosis and Haemostasis|January 12, 2010
Inhibition of acute vascular thrombosis in chimpanzees by an anti-human tissue factor antibody targeting the factor X binding siteJin-an Jiao, Andrew B Kelly, Ulla M Marzec, et al.
Frontiers in Immunology|February 10, 2023
A novel interleukin-2-based fusion molecule, HCW9302, differentially promotes regulatory T cell expansion to treat atherosclerosis in miceXiaoyun Zhu, Qiongzhen Li, Varghese George, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 20, 2022
Immunotherapeutic HCW9218 augments anti-tumor activity of chemotherapy via NK cell-mediated reduction of therapy-induced senescent cellsPallavi Chaturvedi, Varghese George, Niraj Shrestha, et al.
Cancer Immunology Research|October 30, 2015
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal ModelsPeter R Rhode, Jack O Egan, Wenxin Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2018
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid TumorsKim Margolin, Chihiro Morishima, Vamsidhar Velcheti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2021
Bifunctional TGF-β trap/IL-15 protein complex elicits potent NK cell and CD8<sup>+</sup> T cell immunity against solid tumorsBai Liu, Xiaoyun Zhu, Lin Kong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2015
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell LymphomasMaximillian Rosario, Bai Liu, Lin Kong, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2024
A "Prime and Expand" strategy using the multifunctional fusion proteins to generate memory-like NK cells for cell therapyNiraj Shrestha, Michael J Dee, Pallavi Chaturvedi, et al.
The Lancet. Oncology|April 10, 2018
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trialJohn M Wrangle, Vamsidhar Velcheti, Manish R Patel, et al.
Pageof 5